1-9 of 9
Wynne Aherne
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A228: CCT244747 is a novel, potent and selective inhibitor of CHK1 with oral efficacy both alone in neuroblastoma and in combination with genotoxic chemotherapeutic agents.

Michael I. Walton, Paul E. Eve, Angela Hayes, Melanie R. Valenti, Alexis K. de Haven Brandon, Gary Box, Albert Hallsworth, Elizabeth L. Smith, Kathy J. Boxall, Michael Lainchbury, Thomas P. Matthews, Yann Jamin, Simon P. Robinson, G. Wynne Aherne, John C. Reader, Louis Chesler, Florence I. Raynaud, Suzanne E. Eccles, Ian Collins, Michelle D. Garrett
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A228.
https://doi.org/10.1158/1535-7163.TARG-11-A228
Published: 12 November 2011
View article titled, Abstract A228: CCT244747 is a novel, potent and selective inhibitor of CHK1 with oral efficacy both alone in neuroblastoma and in combination with genotoxic chemotherapeutic agents.
Journal Articles

Abstract A235: Structure-guided evolution of potent and selective oral inhibitors of CHK1 through scaffold morphing.

Thomas P. Matthews, Suki Klair, Kwai-Ming J. Cheung, Jane Scanlon, Michael Lainchbury, Nelly Piton, Martin Fisher, Michael Cherry, Kathy Boxall, Michael I. Walton, Isaac M. Westwood, Angela Hayes, Paul Eve, Melanie Valenti, Alexis de Haven Brandon, Gary Box, Rob L. M. van Montfort, David H. Williams, Wynne Aherne, Florence I. Raynaud, Suzanne A. Eccles, Michelle D. Garrett, John C. Reader, Ian Collins
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A235.
https://doi.org/10.1158/1535-7163.TARG-11-A235
Published: 12 November 2011
View article titled, Abstract A235: Structure-guided evolution of potent and selective oral inhibitors of CHK1 through scaffold morphing.
Journal Articles

Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930

Timothy A. Yap, Mike I. Walton, Lisa-Jane K. Hunter, Melanie Valenti, Alexis de Haven Brandon, Paul D. Eve, Ruth Ruddle, Simon P. Heaton, Alan Henley, Lisa Pickard, Gowri Vijayaraghavan, John J. Caldwell, Neil T. Thompson, Wynne Aherne, Florence I. Raynaud, Suzanne A. Eccles, Paul Workman, Ian Collins, Michelle D. Garrett
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (2): 360–371.
https://doi.org/10.1158/1535-7163.MCT-10-0760
Published: 08 February 2011
View article titled, Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
Open the PDF for Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930 in another window
Includes: Supplementary data
Journal Articles

The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

Michael I. Walton, Paul D. Eve, Angela Hayes, Melanie Valenti, Alexis De Haven Brandon, Gary Box, Kathy J. Boxall, G. Wynne Aherne, Suzanne A. Eccles, Florence I. Raynaud, David H. Williams, John C. Reader, Ian Collins, Michelle D. Garrett
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (1): 89–100.
https://doi.org/10.1158/1535-7163.MCT-09-0938
Published: 12 January 2010
View article titled, The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106
Open the PDF for The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106 in another window
Includes: Supplementary data
Journal Articles

Abstract A239: MPS1 (TTK) kinase inhibition selectively kills aneuploid cells

Teeara Rawjee, Martin Rowlands, Craig McAndrew, Mark Stubbs, Christopher J. Lord, Jorge S. Reis‐Filho, Alan Ashworth, Wynne Aherne, Paul Workman, Julian Blagg, Spyridon Linardopoulos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A239.
https://doi.org/10.1158/1535-7163.TARG-09-A239
Published: 10 December 2009
View article titled, Abstract A239: MPS1 (TTK) kinase inhibition selectively kills aneuploid cells
Journal Articles

NVP-AUY922, a novel diarylisoxazole resorcinol HSP90 inhibitor, potently inhibits growth and metastasis of human tumor xenografts

Suzanne Eccles, Swee Sharp, Florence Raynaud, Melanie Valenti, Lisa Patterson, Sharon Gowan, Kathy Boxall, Wynne Aherne, Martin Rowlands, Angela Hayes, Vanessa Martins, Federique Urban, Chrisostomos Prodromou, Laurence Pearl, Karen James, Thomas Matthews, Kwai-Ming Cheung, Andrew Kalusa, Keith Jones, Edward McDonald, Paul Brough, Andrew Massey, Brian Dymock, Martin Drysdale, Paul Workman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B284.
Published: 01 November 2007
View article titled, NVP-AUY922, a novel diarylisoxazole resorcinol HSP90 inhibitor, potently inhibits growth and metastasis of human tumor xenografts
Journal Articles

Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues

Swee Y. Sharp, Chrisostomos Prodromou, Kathy Boxall, Marissa V. Powers, Joanna L. Holmes, Gary Box, Thomas P. Matthews, Kwai-Ming J. Cheung, Andrew Kalusa, Karen James, Angela Hayes, Anthea Hardcastle, Brian Dymock, Paul A. Brough, Xavier Barril, Julie E. Cansfield, Lisa Wright, Allan Surgenor, Nicolas Foloppe, Roderick E. Hubbard, Wynne Aherne, Laurence Pearl, Keith Jones, Edward McDonald, Florence Raynaud, Sue Eccles, Martin Drysdale, Paul Workman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (4): 1198–1211.
https://doi.org/10.1158/1535-7163.MCT-07-0149
Published: 12 April 2007
View article titled, Inhibition of the heat shock protein 90 molecular chaperone <em>in vitro</em> and <em>in vivo</em> by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues
Open the PDF for Inhibition of the heat shock protein 90 molecular chaperone <em>in vitro</em> and <em>in vivo</em> by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues in another window
Includes: Supplementary data
Journal Articles

A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation

Anthea Hardcastle, Peter Tomlin, Clair Norris, Juliet Richards, Matthew Cordwell, Katherine Boxall, Martin Rowlands, Keith Jones, Ian Collins, Edward McDonald, Paul Workman, Wynne Aherne
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (3): 1112–1122.
https://doi.org/10.1158/1535-7163.MCT-06-0496
Published: 15 March 2007
View article titled, A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation
Open the PDF for A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation in another window
Journal Articles

Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity

Lindsay Stimson, Martin G. Rowlands, Yvette M. Newbatt, Nicola F. Smith, Florence I. Raynaud, Paul Rogers, Vassilios Bavetsias, Stephen Gorsuch, Michael Jarman, Andrew Bannister, Tony Kouzarides, Edward McDonald, Paul Workman, G. Wynne Aherne
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (10): 1521–1532.
https://doi.org/10.1158/1535-7163.MCT-05-0135
Published: 14 October 2005
View article titled, Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity
Open the PDF for Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity in another window